Chemed Corporation (CHE)

NYSE: CHE · Real-Time Price · USD
439.36
-2.19 (-0.50%)
May 22, 2026, 4:00 PM EDT - Market closed
Market Cap5.81B -30.2%
Revenue (ttm)2.54B +2.1%
Net Income259.78M -15.9%
EPS18.30 -10.8%
Shares Out 13.22M
PE Ratio24.01
Forward PE17.64
Dividend$2.40 (0.55%)
Ex-Dividend DateMay 28, 2026
Volume162,103
Open441.94
Previous Close441.55
Day's Range437.42 - 445.46
52-Week Range365.21 - 581.20
Beta0.54
AnalystsHold
Price Target446.50 (+1.63%)
Earnings DateApr 23, 2026

About CHE

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides dire... [Read more]

Sector Healthcare
Founded 1970
Employees 15,811
Stock Exchange NYSE
Ticker Symbol CHE
Full Company Profile

Financial Performance

In 2025, Chemed's revenue was $2.53 billion, an increase of 4.06% compared to the previous year's $2.43 billion. Earnings were $265.24 million, a decrease of -12.17%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for CHE stock is "Hold." The 12-month stock price target is $446.5, which is an increase of 1.63% from the latest price.

Price Target
$446.5
(1.63% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Chemed Transcript: RBC Capital Markets Global Healthcare Conference 2026

Admissions and census are growing ahead of expectations, driven by a balanced mix of hospital and non-hospital sources and rapid ramp-up in new Florida markets. CAP mitigation strategies are effective, with new inpatient units and labor expansion supporting future growth. Regulatory scrutiny is welcomed, with a focus on targeted anti-fraud efforts.

3 days ago - Transcripts

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

CINCINNATI, May 18, 2026 (GLOBE NEWSWIRE) -- Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company's 2026 annual stockholders' meeting.

4 days ago - GlobeNewsWire

Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference

CINCINNATI, May 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May...

10 days ago - GlobeNewsWire

Chemed Transcript: Bank of America Global Healthcare Conference 2026

Census and margin outlooks were raised for the hospice segment, supported by improved referral management and regulatory changes. Expansion continues via de novo growth and selective acquisitions, while digital marketing and operational efficiencies drive recovery in the non-healthcare segment.

10 days ago - Transcripts

Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026

CINCINNATI, May 05, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2026 Health Care Conference on Tuesday,...

18 days ago - GlobeNewsWire

Chemed price target raised to $436 from $422 at RBC Capital

RBC Capital raised the firm’s price target on Chemed (CHE) to $436 from $422 and keeps a Sector Perform rating on the shares. Shares rallied over 10% on Friday following…

26 days ago - TheFly

Chemed Earnings Call Transcript: Q1 2026

VITAS delivered strong Q1 2026 results, raising full-year guidance for ADC, revenue, and EPS, while Roto-Rooter showed early signs of recovery despite higher marketing costs and weather disruptions. Franchise acquisitions and improved collections supported growth.

4 weeks ago - Transcripts

Chemed Earnings release: Q1 2026

Chemed released its Q1 2026 earnings on April 24, 2026, summarizing the period's financial results.

4 weeks ago - Filings

Chemed Slides: Q1 2026

Chemed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 24, 2026.

4 weeks ago - Filings

Chemed Quarterly report: Q1 2026

Chemed has published its Q1 2026 quarterly earnings report on April 24, 2026.

4 weeks ago - Filings

Chemed reports Q1 adjusted EPS $5.65, consensus $5.30

Reports Q1 revenue $657.5M, consensus $649.82M. As of March 31, Chemed (CHE) had total cash and cash equivalents of $16.9M and $91.2M in long-term debt.

4 weeks ago - TheFly

Chemed raises FY26 adjusted EPS view to $24.00-$24.75 from $23.25-$24.25

Consensus $23.88. The company said, “Historically, we do not give quarterly updates to guidance. Due to the materially improved performance of VITAS, coupled with the level of share repurchases in…

4 weeks ago - TheFly

Chemed Reports First-Quarter 2026 Results

Full-Year Guidance Increased Due To: Strong VITAS Performance Re-purchase of 500,000 Shares in the Quarter Two Roto-Rooter Franchises Purchased for $20.6 Million CINCINNATI, April 23, 2026 (GLOBE NEWS...

4 weeks ago - GlobeNewsWire

This Newsletter Has a Multidecade Market-Beating Record. How It Finds Winning Stocks—and Dodges Losers.

Investment Quality Trends' yield-focused model portfolios have beaten the broad stock market since 1986.

Other symbols: RIO
4 weeks ago - Barrons

Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement

CINCINNATI, April 13, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation ("Chemed") (NYSE:CHE) announced that it has entered into an Amended and Restated Credit Agreement for its Credit Facility (“Credit Agr...

5 weeks ago - GlobeNewsWire

Chemed Proxy statement: Proxy filing

Chemed filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.

6 weeks ago - Filings

Chemed Proxy statement: Proxy filing

Chemed filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.

6 weeks ago - Filings

Chemed To Report First Quarter 2026 Earnings April 23, Related Conference Call To Be Held On April 24

CINCINNATI, April 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2026, on Thursday, April 23, ...

7 weeks ago - GlobeNewsWire

Chemed’s Roto-Rooter purchases territory and assets of two franchises

Roto-Rooter Services Company, a wholly owned subsidiary of Chemed (CHE) Corporation, announced it has purchased the territory and assets of the franchises operating in San Francisco, California and Fo...

7 weeks ago - TheFly

Roto-Rooter Completes Acquisitions for Two Significant Territories

Two acquisitions completed by Roto-Rooter Services Company for combined $20.6 million in Fort Worth, Texas and San Francisco, California on March 31, 2026.

7 weeks ago - GlobeNewsWire

Oppenheimer explores Chemed value in possible Roto-Rooter split

Oppenheimer still believes Chemed (CHE) can unlock Roto-Rooter’s value operationally. However, it makes sense to looking at the value of the two companies separately given their lack of synergies and…

7 weeks ago - TheFly

Chemed Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Management expressed confidence in VITAS's growth and margin outlook, driven by strong Florida performance and new market entries, while Roto-Rooter guidance remains conservative amid ongoing marketing and collection challenges. Strategic alternatives for Roto-Rooter will be considered if recovery stalls in 2026.

2 months ago - Transcripts

Chemed Corporation to Present at the Oppenheimer 36th Annual Healthcare Conference

CINCINNATI, March 12, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 36th Annual Healthcare Conference on Thursda...

2 months ago - GlobeNewsWire

Chemed price target lowered to $500 from $580 at Oppenheimer

Oppenheimer analyst Michael Wiederhorn lowered the firm’s price target on Chemed (CHE) to $500 from $580 and keeps an Outperform rating on the shares. The firm notes Chemed reported a…

3 months ago - TheFly

Chemed downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded Chemed (CHE) to Sector Perform from Outperform with a price target of $422, down from $572. The firm cites near and longer-term Roto-Rooter margin uncertainty for the…

3 months ago - TheFly